Biogened S.A.

BGD

PLBIOGN00018

Pharmaceuticals

End-of-day quote Warsaw S.E. Other stock markets 03:30:00 17/07/2024 am IST			5-day change	1st Jan Change
19.9 ^PLN	-2.45%		-7.01%	+10.56%

15/05	Biogened S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
14/02	Biogened S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Biogened S A : Raport kwartalny za II kwartał 2020 roku

August 14, 2020 at 10:48 pm IST

Raport kwartalny za II kwartał 2020 roku. Biogened Spółka Akcyjna

14-08-2020 | Kwartalny | EBI | 10/2020

Zarząd Biogened S.A. przekazuje w załączonym dokumencie raport okresowy kwartalny za I kwartał 2020 roku.

Podstawa prawna:
§5 ust. 1 pkt 1 Załącznika nr 3 do Regulaminu Alternatywnego Systemu Obrotu - Informacje bieżące i okresowe przekazywane w alternatywnym systemie obrotu na rynku NewConnect.

Andrzej Grzegorzewski - Prezes Zarządu
Barbara Biegańska - Wiceprezes Zarządu

Do pobrania

Raport kwartalny za I kwartał 2020 roku. Biogened Spółka Akcyjna

15-05-2020 | Kwartalny | EBI | 5/2020

Zarząd Biogened S.A. przekazuje w załączonym dokumencie raport okresowy kwartalny za I kwartał 2020 roku.

Podstawa prawna:
§5 ust. 1 pkt 1 Załącznika nr 3 do Regulaminu Alternatywnego Systemu Obrotu - Informacje bieżące i okresowe przekazywane w alternatywnym systemie obrotu na rynku NewConnect.

Andrzej Grzegorzewski - Prezes Zarządu
Barbara Biegańska - Wiceprezes Zarządu

Attachments

Original document
Permalink

Disclaimer

Biogened SA published this content on 14 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 August 2020 17:17:05 UTC

Latest news about Biogened S.A.

Biogened S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Biogened S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	14/02	CI
Biogened S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Biogened S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Biogened S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Biogened S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Biogened S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	14/23/14	CI
Biogened S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	14/23/14	CI
Biogened S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Biogened S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Biogened S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Biogened S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	14/22/14	CI
Biogened S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	14/22/14	CI
Biogened S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/21/12	CI
Biogened S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/21/13	CI
Biogened S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	12/21/12	CI
Biogened S.A. Announces Dividend, Payable on November 11, 2020	29/20/29	CI
Biogened S.A. Receives FDA Approval for Vumerity for Multiple Sclerosis	11/19/11	CI
Biogened S.A. announced that it expects to receive PLN 0.5 million in funding	19/17/19	CI
Biogened S.A. announced that it has received PLN 3 million in funding	29/16/29	CI
Biogened S.A. announced that it expects to receive PLN 6 million in funding	20/16/20	CI
Enrav Fizan acquired 32.2% stake in Biogened S.A..	02/16/02	CI
Bioniq Limited acquired additional 6.96% stake in Biogened S.A..	24/16/24	CI
LAVINIA I Sp. z o.o. Sp. k. acquired additional 4.86% stake in Biogened S.A..	24/16/24	CI
Biogened S.A. announced that it expects to receive PLN 5 million in funding.	15/15/15	CI

Chart Biogened S.A.

Duration

Period

More charts

Company Profile

Biogened SA is a Poland-based company active in the healthcare sector. The Company is engaged in production and distribution of generic pharmaceuticals in psychiatry, neurology and oncology, as well as development, production and distribution of dermocosmetics and diet supplements. The Companyâs product portfolio includes: Polmantis and SST Salvia Stimulating Tablets (pharmaceuticals), Dermedic, Ellexir, Herba Botanic and Novoscabin (dermocosmetics), and Fibers, Prolady, Futimal and Dermedic Caps (diet supplemenst). As of March 31, 2012, Life Science Technologies NV held an 80.92% stake in the capital.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
BIOGENED S.A.	+10.56%	12.44M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+26.58%	45.33B
OTSUKA HOLDINGS CO., LTD.	+38.49%	25.36B
SANDOZ GROUP AG	+27.75%	16.7B
CIPLA LIMITED	+20.89%	14.59B
ZYDUS LIFESCIENCES LIMITED	+72.03%	14.26B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-10.35%	6.67B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.07%	5.62B
STADA ARZNEIMITTEL	-8.87%	5.73B